Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Adamis Pharmaceuticl (ADMP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 67,153
  • Shares Outstanding, K 47,291
  • Annual Sales, $ 15,090 K
  • Annual Income, $ -39,010 K
  • 60-Month Beta 1.53
  • Price/Sales 4.36
  • Price/Cash Flow N/A
  • Price/Book 1.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.12
  • Number of Estimates 2
  • High Estimate -0.11
  • Low Estimate -0.13
  • Prior Year -0.29
  • Growth Rate Est. (year over year) +58.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.25 +13.60%
on 06/05/19
1.88 -24.47%
on 05/20/19
-0.48 (-25.26%)
since 05/17/19
3-Month
1.25 +13.60%
on 06/05/19
2.69 -47.21%
on 03/18/19
-1.29 (-47.60%)
since 03/15/19
52-Week
1.25 +13.60%
on 06/05/19
5.10 -72.16%
on 07/02/18
-2.53 (-64.05%)
since 06/15/18

Most Recent Stories

More News
Adamis Pharmaceuticals Provides Update on Its Higher Dose Naloxone Injection Product

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the receipt of Adamis' amendment to its previously submitted New Drug...

ADMP : 1.42 (+2.16%)
Adamis Pharmaceuticals Announces Conditional Acceptance by FDA of Proprietary Name for Higher Dose Naloxone Product

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today conditional acceptance by the U.S. Food and Drug Administration (FDA) of the proposed brand name for the company's high dose naloxone product...

ADMP : 1.42 (+2.16%)
Adamis Pharmaceuticals (ADMP) Reports Q1 Loss, Misses Revenue Estimates

Adamis (ADMP) delivered earnings and revenue surprises of -11.76% and -17.48%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

ADMP : 1.42 (+2.16%)
Adamis: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Adamis Pharmaceuticals Corp. (ADMP) on Thursday reported a loss of $8.9 million in its first quarter.

ADMP : 1.42 (+2.16%)
Adamis Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the first quarter ended March 31, 2019 and provided a business update.

ADMP : 1.42 (+2.16%)
Adamis Pharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ("Adamis"), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas including respiratory...

ADMP : 1.42 (+2.16%)
Market Trends Toward New Normal in GrafTech International, Avinger, OraSure Technologies, Adamis Pharmaceuticals, Crinetics Pharmaceuticals, and Wayside Technology Group -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of GrafTech International Ltd....

OSUR : 8.61 (+0.82%)
CRNX : 22.77 (+5.47%)
WSTG : 11.51 (-0.69%)
ADMP : 1.42 (+2.16%)
EAF : 10.81 (-0.83%)
AVGR : 0.47 (+4.84%)
Adamis Pharmaceuticals Announces 2018 Financial Results and Provides Business Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the year ended December 31, 2018 and provided a business update.

ADMP : 1.42 (+2.16%)
Adamis Pharmaceuticals Announces FDA Acceptance for Review of the New Drug Application of Its Higher Dose Naloxone Injection Product Candidate

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced that theU.S. Food and Drug Administration("FDA") has accepted for review the company's New Drug Application ("NDA") for its...

ADMP : 1.42 (+2.16%)
Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ADMP : 1.42 (+2.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

See More Share

Trade ADMP with:

Business Summary

Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned...

See More

Key Turning Points

2nd Resistance Point 1.52
1st Resistance Point 1.47
Last Price 1.42
1st Support Level 1.36
2nd Support Level 1.30

See More

52-Week High 5.10
Fibonacci 61.8% 3.63
Fibonacci 50% 3.17
Fibonacci 38.2% 2.72
Last Price 1.42
52-Week Low 1.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar